louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01769404: A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes
Official title: Evaluation of the Counter-Regulatory Response to Hypoglycaemia Following LY2605541 Administration Compared to Insulin Glargine in Patients With Type 1 Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Diabetes Mellitus, Type 1
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2013-01-16
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: This study has 2 parts. Each participant will receive a daily injection of LY2605541 during one treatment period and a daily injection of insulin glargine during one treatment period. Each treatment period is 2 to 3 weeks and is followed by a procedure to lower blood sugar levels to see how the body recovers after each treatment.


Eligibility criteria: Inclusion Criteria:

* Type 1 diabetic for more than 1 year with glycated hemoglobin (HbA1c) less than 9%
* Otherwise fit and healthy
* Nonsmoker

Exclusion Criteria:

* Taking medication or supplements other than insulin to control diabetes
* Suffered a hypoglycemic event in the last 12 months that required hospitalization or has poor awareness of hypoglycemia

Primary outcomes:
measure: Concentration of Epinephrine
timeFrame: 30, 15, and 0 minutes Preclamp; 10, 20, and 30 minutes Post-Clamp
Secondary outcomes:
measure: Amount of Glucose Required to Reach Blood Glucose (BG) of 72 mg/dL
timeFrame: 30, 15, and 0 minutes Preclamp; 10, 20, and 30 minutes Post-Clamp
measure: Amount of Glucose Required to Maintain BG of 72 mg/dL
timeFrame: 30, 15, and 0 minutes Preclamp; 10, 20, and 30 minutes Post-Clamp
measure: Concentration of Cortisol
timeFrame: 30, 15, and 0 minutes Preclamp; 10, 20, and 30 minutes Post-Clamp
measure: Concentration of Glucagon
timeFrame: 30, 15, and 0 minutes Preclamp; 10, 20, and 30 minutes Post-Clamp
measure: Concentration of Growth Hormone
timeFrame: 30, 15, and 0 minutes Preclamp; 10, 20, and 30 minutes Post-Clamp
measure: Concentration of Norepinephrine
timeFrame: 30, 15, and 0 minutes Preclamp; 10, 20, and 30 minutes Post-Clamp
Other outcomes:
Locations:
city: Neuss
country: Germany
facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT05770804: Young Women on Sexual and Reproductive Health Knowledge and Stigma Levels
Official title: The Effect of Education Given to Young Women on Sexual and Reproductive Health Knowledge and Stigma Levels: A Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sexuality
Stigmatization
Inflammation
Keywords: sexual health
knowledge
Stigma
Lead sponsor: Sakarya University
Sponsor class: OTHER
First posted: 2023-03-15
Enrollment: 90
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 24
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Aim: Failure to exercise reproductive and sexual rights can increase the risk of unwanted pregnancies, HIV and sexually transmitted infections, sexual coercion and violence, especially in young women. All of these situations affect the physical and mental health of young girls, as well as the health of their families.For this reason, The Effect of Education Given to Young Women on Sexual and Reproductive Health Knowledge and Stigma Levels: A Randomized Controlled Study was planned.

Material and method: The research was conducted as a randomized controlled experimental study. The universe of the research consisted of female students studying at the Faculty of Health Sciences of Ağrı İbrahim Çeçen University between January and June 2022. The sample consisted of individuals who were studying at the Faculty of Health Sciences of Ağrı İbrahim Çeçen University between the same dates and who met the inclusion criteria of the research. "Descriptive Feature Form", "Sexual and Reproductive Health Stigma Scale for Young Women" and sexual health knowledge test were used to collect data. In the analysis of data; percentile distribution, chi-square, Fisher-Freeman- Halton Exact test, paired samples test, t-test in independent groups, Friedman Test, One Way ANOVA test, and post hoc analyzes (Bonferroni, Games Howell, Dunn) were used.


Eligibility criteria: Inclusion Criteria: Be between the ages of 18-24. Agree to participate voluntarily. -

Exclusion Criteria: be over 24 years old

-

Primary outcomes:
measure: Face to face group
timeFrame: 6 weeks
measure: Face to face group
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Sakarya
country: Turkey
facility: Sakarya University
Study officials:
affiliation: Sakarya University
name: Metin YILDIZ, Asst.Prof.Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02030704: CCTA-based Coronary Plaque Characterization and High-sensitive Troponin T for the Prediction of Cardiovascular Outcomes
Official title: Comprehensive 'Bio-Imaging' Using Quantitative Coronary Plaque Composition Assessment and the High-sensitive Troponin T for the Prediction of Cardiac Outcomes.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease
Noninvasive Plaque Characterization
Lead sponsor: University Hospital Heidelberg
Sponsor class: OTHER
Collaborators: name: Semmelweis University Heart and Vascular Center
name: Heidelberg University
First posted: 2014-01-08
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Consecutive patients scheduled to undergo CCTA

Brief summary: To determine the ability of semi-automated plaque assessment in cardiac computed tomography angiography (CCTA) and high sensitive troponin T (hsTnT) for the risk stratification of patients at intermediate risk for coronary artery disease (CAD).


Eligibility criteria: Inclusion Criteria:

* Clinical indication for CCTA according to the current appropriate use criteria

Exclusion Criteria:

* non-sinus rhythm
* acute coronary syndromes
* cardiomyopathies
* moderate or severe valvular disease
* elevated serum creatinine (\>1.5 mg/dl)
* history or ECG signs of previous myocardial infarction
* severe iodine allergy.

Primary outcomes:
measure: Cardiac death
timeFrame: two years
measure: Nonfatal myocardial infarction
timeFrame: two years
Secondary outcomes:
measure: Myocardial revascularization including PCI and CABG
timeFrame: two years
Other outcomes:
Locations:
city: Heidelberg
country: Germany
facility: University of Heidelberg, Department of Cardiology
state: Baden-Wuerttemberg
city: Budapest
country: Hungary
facility: MTA-SE Lendület Cardiovascular Imaging Research Group, Heart and Vascular Center, Semmelweis University
Study officials:
affiliation: University of Heidelberg, Department of Cardiology, Heidelberg, Germany.
name: Grigorios Korosoglou, Prof. Dr. med.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Korosoglou G, Mueller D, Lehrke S, Steen H, Hosch W, Heye T, Kauczor HU, Giannitsis E, Katus HA. Quantitative assessment of stenosis severity and atherosclerotic plaque composition using 256-slice computed tomography. Eur Radiol. 2010 Aug;20(8):1841-50. doi: 10.1007/s00330-010-1753-3. Epub 2010 Mar 20.
Clinical trial NCT05204004: The Sunrise OSA Trial
Official title: A Prospective, Multicentre, Randomised, Blinded Study of Obstructive Sleep Apnoea Detection Using the Sunrise Solution
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obstructive Sleep Apnea
Lead sponsor: Royal Brompton & Harefield NHS Foundation Trust
Sponsor class: OTHER
Collaborators: name: NHS Highlands
First posted: 2022-01-24
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A prospective, randomised, blinded pilot study
Primary purpose: DIAGNOSTIC

Brief summary: A prospective, randomised, blinded pilot study comparing the Sunrise solution and overnight polygraphy for the diagnosis of OSA in adult patients. Patients under investigation for OSA will use both devices simultaneously for a single overnight sleep study. They will be randomised to receive their treatment decision based on either the Sunrise solution or polygraphy. A retrospective check of their diagnosis will be done.


Eligibility criteria: Inclusion Criteria:

1. Aged ≥18
2. Ability and willingness to provide informed consent
3. Patient referred for suspected OSA
4. BMI \>28 kg/m2
5. Epworth Sleepiness Score \>12
6. Reported snoring (criterion may be ignored if patient sleeps alone)
7. Patient able to use a smartphone application and having an internet connection at home

Exclusion Criteria:

1. Patient already treated for OSA
2. Patient has PSV or HGV driving license
3. Unstable cardiac disease
4. Supplemental oxygen
5. Known secondary sleep pathology e.g. Periodic Limb Movement Syndrome, Narcolepsy, Circadian Disorder, Obesity Hypoventilation Syndrome
6. Concerns about sleepy driving or any other potentially dangerous symptom from physician or urgent referral from GP when patient has been told to stop driving
7. Pregnant woman, parturient, nursing mother, person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure
8. Patient whose beard is too thick to wear the Sunrise device, and who does not wish to shave
9. Patient with acrylic or painted fingernails, who does not wish to remove acrylic or paint

Primary outcomes:
measure: Time to treatment decision
timeFrame: From date of sleep study device dispatch until the date of treatment decision, assessed typically within 1 month but up to 6 months
Secondary outcomes:
measure: Time to treatment decision; RBH vs NHS Scotland Sleep Service
timeFrame: From date of sleep study device dispatch until the date of treatment decision, assessed typically within 1 month but up to 6 months
measure: AHI
timeFrame: After completion of the sleep studies and data from both devices is available; typically within 1 month but up to 6 months
Other outcomes:
Locations:
city: Inverness
country: United Kingdom
facility: Raigmore Hospital
city: London
country: United Kingdom
facility: Royal Brompton Hospital
Study officials:
References:
Clinical trial NCT00257504: Central Blood Volume in Hypotensive Dialysis Patients
Official title: Registration of Central Blood Volume in Hypotensive Dialysis Patients - a Comparison of Thoracic Impedance and Central Venous Saturation Monitoring
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Intradialytic Hypotension
Lead sponsor: Danish State Hospital
Sponsor class: OTHER
First posted: 2005-11-23
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: OTHER

Brief summary: The purpose of the study is to test whether hypotensive episodes during dialysis - caused by withdrawal of fluid drom the circulation - can be predicted by means of two harmless monitoring techniques.


Eligibility criteria: Inclusion Criteria:

* Chronic hemodialysis patients with central vascular access

Exclusion Criteria:

* Patients below 18 years of age
* Patients unable to give informed consent

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Danish State Hospital
Study officials:
affiliation: Danish State Hospital
name: Søren D Ladefoged, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02289404: A Study to Evaluate the Food Effect on the Pharmacokinetics of NVP-1203
Official title: Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of NVP-1203 in Healthy Adult Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: NVP Healthcare
Sponsor class: INDUSTRY
First posted: 2014-11-13
Enrollment: 39
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate food effect on the pharmacokinetics of NVP-1203

Detailed description: This study is designed as randomized, open-label, crossover assignment for evaluate the food effect on the pharmacokinetics of NVP-1203 in healthy adult subjects

Eligibility criteria: Inclusion Criteria:

* healthy adult subjects who signed informed consent

Exclusion Criteria:

* Subjects has a history of allergy reaction of study drug ingredient
* Subjects participated in another clinical trial within 3 months prior to administration of the study drug
* Inadequate subject for the clinical trial by the investigator's decision

Primary outcomes:
measure: Pharmacokinetics : Cmax
timeFrame: 0-24 hours
measure: Pharmacokinetics : AUCt
timeFrame: 0-24 hours
Secondary outcomes:
measure: Pharmacokinetics : AUCinf
timeFrame: 0-24 hours
measure: Pharmacokinetics : Tmax
timeFrame: 0-24 hours
measure: Pharmacokinetics : t1/2
timeFrame: 0-24 hours
Other outcomes:
Locations:
city: Daegu
country: Korea, Republic of
facility: Kyungpook National University Hospital
state: Dongdeok-ro
Study officials:
affiliation: Kyungpook National University Hospital
name: Yoon Y Ran, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02944604: The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Breastcancer
Lead sponsor: Peking University
Sponsor class: OTHER
First posted: 2016-10-26
Enrollment: 240
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer who were treated with intensive chemotherapy for prevention of neutrophil reduction.


Eligibility criteria: Inclusion Criteria:

1.18-65 years old, gender no limited.

2.Breast cancer diagnosed by pathology.

3.Did not receive chemotherapy previously and plans to receive 4 cycles intensive EC (epirubicin, cyclophosphamide) treatment.

4.No obvious blood system disease, ANC(absolute neutrophil count)≥ 1.5 × 10\^9/L, PLT（Platelet）≥80×10\^9 /L, Hb（hemoglobin）≥75g/L, WBC（White blood cell ）≥3×109/L, and no bleeding tendency.

5.KPS (Karnofsky performance status) score≥70.

6.Expected survival≥3 months.

7.Written informed consent are acquired.

Exclusion Criteria:

1. Severe or uncontrolled infection.
2. Sensitive to the product or other genetically engineered biological products from Escherichia coli strains.
3. Mental or nervous system disorders.
4. Severe heart, lung and central nervous system disorders.
5. Pregnant or lactating women.
6. TBIL(total bilirubin ), ALT（alanine aminotransferase）,AST（glutamic-oxalacetic transaminase） \> 2.5×ULN（upper limit of normal）; if it were caused by liver metastases, TBIL, ALT,AST \>5×ULN.
7. Cr（creatinine） \>1.5×ULN.

Primary outcomes:
measure: Incidence of chemotherapy delay
timeFrame: 60 days after the first chemotherapy
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University Cancer Hospital
state: Beijing
Study officials:
affiliation: Peking University Cancer Hospital & Institute
name: Tao Ouyang, MD
role: STUDY_CHAIR
References:
Clinical trial NCT04645004: Antenatal Platelet Response on Aspirin: a Pharmacokinetic Study Through Pregnancy
Official title: Impact of Maternal Aspirin Tehrapy on the Maternal/Fetal Unit at Delivery: a Study of Aspirin Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics Through Pregnancy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Preeclampsia
Lead sponsor: Thomas Jefferson University
Sponsor class: OTHER
Collaborators: name: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
name: March of Dimes
First posted: 2020-11-25
Enrollment: 20
Sex: FEMALE
Minimum age (years): 13
Maximum age (years): 55
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: One arm PK/PD study of aspirin in pregnancy1
Primary purpose: OTHER

Brief summary: Longitudinal pharmacokinetic and pharmacodynamic study in first and third trimester of pregnancy

Detailed description: This will be a longitudinal addition to an existing R21cohort enrolled in the first trimester to include a first and third trimester assessment of pharmacokinetics/pharmacodynamics (PK/PD) of aspirin and how individual factors impact aspirin PK/PD in pregnancy.

Eligibility criteria: Inclusion Criteria:

* \<16 weeks' gestational age
* Singleton pregnancy
* Plan to take 81mg aspirin due to high risk history (below), but not yet initiated
* ≥1 risk factor:

  * Chronic hypertension
  * Type I or II diabetes
  * Previous preeclampsia
  * Renal disease
  * Autoimmune disease (SLE) OR

    ≥2 risk factor:
  * Nulliparity
  * IVF pregnancy
  * Black race or socioeconomic disadvantaged
  * BMI\>30
  * Prior adverse pregnancy outcome

Exclusion Criteria:

* Contraindication to aspirin
* Current or planned use of any other anticoagulation
* Current need for dialysis
* Use of aspirin therapy prior to enrollment in the current pregnancy
* Thrombocytopenia (\<150)
* Other known platelet disorder/thrombophilia at enrollment

Primary outcomes:
measure: salicylic acid level
timeFrame: 24 hour
measure: serum thromboxane
timeFrame: 4 week post initiation
measure: PFA-100
timeFrame: 4 week post initiation
Secondary outcomes:
measure: Urinary thromboxane
timeFrame: 4 week post initiation
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Thomas Jefferson University Hospital
state: Pennsylvania
Study officials:
affiliation: Thomas Jefferson University
name: Rupsa C Boelig, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00482404: Effects of Romantic Affection on Blood Chemistry and Immune Parameters
Official title: Study of the Effects of Romantic Affection on Blood Lipids, Blood Glucose, C-Reactive Protein, and Antibodies to Latent Epstein-Barr Virus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Stress
Hypercholesterolemia
Lead sponsor: Arizona State University
Sponsor class: OTHER
Collaborators: name: National Institute of Mental Health (NIMH)
First posted: 2007-06-05
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This trial tests the hypothesis that increasing nonverbal affection in romantic relationships will improve blood lipid parameters (total cholesterol, high and low density lipoproteins, triglycerides), blood glucose, and immune parameters (C-reactive protein and antibodies to latent Epstein-Barr virus). 52 healthy cohabiting romantic couples took part. In half of the couples, one partner increased the frequency of romantic kissing with the other partner during the six-week trial. The other couples received no such instruction. Blood tests performed before and after the trial were used to assess the health outcomes.


Eligibility criteria: Inclusion Criteria:

* 18+ years of age;
* English-speaking;
* Current co-habitation with romantic partner

Exclusion Criteria:

* History of hypercholesterolemia;
* Current pregnancy;
* Current use of blood-thinning agents;
* Greater than moderate anxiety about giving capillary blood;
* Weight of less than 110 pounds

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Arizona State University
name: Kory Floyd, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02414204: Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula
Official title: Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Improve Endothelial Function and Decrease Vascular Stenosis
Keywords: Arteriovenous Fistulas (AVFS)
Hemodialysis Fistula Maturation (HFM)
Flow-Mediated Dilation (FMD)
Nitroglycerin-Mediated (NMD)
Venous Plethysmography (VP)
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
First posted: 2015-04-10
Enrollment: 4
Sex: ALL
Minimum age (years): 19
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients with stage IV and V chronic kidney disease and end stage renal disease requiring hemodialysis at University of Alabama at Birmingham (UAB) Dialysis Clinics will be recruited from the UAB Vascular Access Clinic, which has been the site for recruitment of patients requiring new vascular access for the last 10 years.

Detailed description: The main purpose of this research study is to conduct a research study to determine if Sildenafil compared to placebo will improve the vascular health of arteries and veins before arteriovenous fistula creation (shunt) and how quickly your veins and arteries dilate and increase in blood flow after fistula creation. An arteriovenous fistula (shunt) is a connection between the artery and vein in the arm for dialysis use. Another purpose of this study is to determine if Sildenafil reduces the blood and tissue levels of oxidants prior to fistula creation. Oxidants are harmful substances in the body that damage the cells tissues, and organs.

Eligibility criteria: Inclusion Criteria:

1. Age ≥19 years of age male or female
2. Chronic Kidney Disease Stage IV or V patients or End Stage Renal Disease Patient requiring arteriovenous fistula surgery

Exclusion Criteria:

1. Patient currently on nitrate therapy or any nitric oxide donor in any form
2. Patient currently on protease inhibitor or non-nucleoside reverse transcriptase inhibitor
3. Patient with resting systolic blood pressure \<90 mm Hg and diastolic blood pressure \< 50 mm Hg.
4. Patient life expectancy \< nine months.
5. Patient unable or unwilling to meet study requirements.

Primary outcomes:
measure: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group
timeFrame: 2 weeks
Secondary outcomes:
measure: Number of Participants With a Change in Blood Flow Rate
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham
state: Alabama
Study officials:
affiliation: University of Alabama at Birmingham
name: Timmy Lee, MD
role: PRINCIPAL_INVESTIGATOR
References: